07 Jan 2001

Dayamineral jarabe - España

Updated: 07 Jan 2001

Dayamineral jarabe jarabe 125 ml

Profilaxis y tratamiento de estados carenciales de vitaminas y minerales: Embarazo, lactancia, astenia, crecimiento, etc.

Dayamineral jarabe Description, Presentation and Dosage

Dayamineral jarabe Description

Dayamineral jarabe Drug Class Description

Polivitaminicos con minerales

Dayamineral jarabe Drug Description

JARABE

Dayamineral jarabe Presentation

Dayamineral jarabe Presentation

Lactantes: 1/2 cucharadita/día. Niños: 1 cucharadita/día. Adultos: 2 cucharaditas/día.

Dayamineral jarabe Manufacturer

ABBOTT LABORATORIES

Related Learning Zones

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Type 1 Childhood Diabetes CME

Type 1 Childhood Diabetes CME

In this EACCME-accredited online CME activity Individual Patient Management in Type 1 Childhood Diabetes, healthcare professionals will learn how to assess the psychosocial wellbeing of young patients with type 1 diabetes. 

Upon successful completion of this activity, healthcare professionals (such as endocrinologists, paediatricians, paediatric endocrinologists, diabetes specialists, specialist nurses, primary care physicians) will be awarded 1 European CME credit (ECMEC).

Dayamineral jarabe Dosage

Dayamineral jarabe Precautions, Reactions and Contraindications

Dayamineral jarabe Special Precautions

Related Drugs - Gastroenterologia

Back to top